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Since 1963, evidence has accumulated that suggests boron is a safe and effective treatment for some forms of arthritis. The initial evidence was
that boron supplementation alleviated arthritic pain and discomfort of the author. This was followed by findings from numerous other observations
epidemiologic and controlled animal and human experiments. These findings included a) analytical evidence of lower boron concentrations in femur
heads, bones, and synovial fluid from people with arthritis than from those without this disorder; b) observation evidence that bones of patients
using boron supplements are much harder to cut than those of patients not using supplements; c) epidemiologic evidence that in areas of the world
where boron intakes usually are 1.0 mg or less/day the estimated incidence of arthritis ranges from 20 to 70%, whereas in areas of the world
where boron intakes are usually 3 to 10 mg, the estimated incidence of arthritis ranges from 0 to 10%; d) experimental evidence that rats with
induced arthritis benefit from orally or intraperitoneally administered boron; e) experimental evidence from a double-blind placebo-boron supplemen-
tation trial with 20 subjects with osteoarthritis. A significant favorable response to a 6 mg boron/day supplement was obtained; 50% of subjects
receiving the supplement improved compared to only 10% receiving the placebo. The preceding data indicate that boron is an essential nutrient for
healthy bones and joints, and that further research into the use of boron for the treatment or prevention of arthritis is warranted. - Environ Health
Perspect 102(Suppl 7):83-85 (1994)
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Introduction
In 1963, I hypothesized that the lack of
dietary boron would enhance the occur-
rence and severity of some forms ofarthri-
tis, or that boron supplementation could
alleviate arthritic conditions in animals
and humans. This hypothesis was the
result ofthe alleviation of my own arthritic
pain, swelling, and stiffness by boron sup-
plementation (6 mg elemental boron/day
as sodium tetraborate).
Shortly thereafter, other people with
arthritis were convinced to try boron sup-
plementation; many had their arthritic
symptoms alleviated. Between 1976 and
1981, 90,000 bottles of elemental boron
(100 tablets containing 3 mg, called Bor-
Rex) were sold without advertising; word-
of-mouth recommendations of satisfied
users was all that was necessary. After
receiving hundreds of positive comments
from others who had tried boron supple-
mentation, I presented my experiences and
successes to the Australian and New
Zealand Association for the Advancement
of Science in Auckland, New Zealand in
1979, and at the International Symposium
on Trace Elements in Man and Animals-4
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(TEMA-4) held in Perth, Australia, in
1981 (1).
In the TEMA-4 paper, I presented data
that showed that arthritic femur heads
contained half the boron content of
healthy femur heads (29.6 ppm vs 56
ppm). Subsequently, similar findings were
obtained by Havercroft and Ward (2);
they found lower boron concentrations in
bones and synovial fluid from people with
rheumatoid arthritis than from those with-
out this disorder.
In 1981, Australia instituted a regula-
tion that declared boron and its com-
pounds were poison in any concentration.
This regulation effectively stopped the sale
of boron supplements in Australia. This
action impelled me to obtain scientific evi-
dence for the dietary need for boron. My
first research efforts were directed towards
establishing an epidemiologic relationship
between arthritis and low boron exposure.
The results ofthis research have been pub-
lished (3,4). The findings suggested that
in areas of the world where boron intakes
usually were 1 mg or less/day, the estimat-
ed incidence ofarthritis ranged from 20 to
70%. On the other hand, in areas of the
world where boron intakes were usually 3
to 10 mg, the estimated incidence of
arthritis ranged from 0 to 10%.
While the epidemiologic evidence was
accumulating, other findings appeared that
supported the concept that boron is benefi-
cial to bone health; some of these were
reviewed recently (5). They include the
observations of surgeons that bones of
patients who use boron supplements are
much harder to cut than bones of patients
who do not use supplements, the clinical
observation that boron supplements appar-
ently accelerate the healing of broken
bones, and that rats given an arthritic adju-
vant developed less inflammation and
arthritis when administered boron either
orally or intraperitoneally. It also has been
reported recently that boron alone and in
combination with garlic oil showed
antiarthritic activity against formaldehyde-
induced arthritis in rats (6).
Materials and Methods
To date, the most convincing evidence that
boron may be useful in the treatment of
arthritis was the result of a double-blind
trial conducted at the Royal Melbourne
Hospital, Australia, between 1983 and
1987 (7). Twenty patients presenting radi-
ographically confirmed osteoarthritis were
recruited to the trial, which compared daily
oral dosages of6 mg boron/day (55 mg of
sodium tetraborate decahydrate) to a place-
bo (66% dextrose, 33% dicalcium phos-
phate, 1% magnesium stearate) in the
treatment of their arthritis symptoms.
These subjects had exhibited arthritis
symptoms for fewer than 10 years dura-
tion. The patients were under 75 years of
age and free of cardiac and renal disease.
The patients were assessed three times-
prior to taking the tablets, after 3 weeks on
the tablets, and after 8 weeks on the tablets.
Environmental Health Perspectives 83R. E. NEWNHAM
The following scale was used to grade the
responses to treatment: a) completely
cured (i.e., pain-free and no restriction of
movement); b) much better but not com-
pletely cured; c) only slightly better; d) no
different; e) slightly worse;f) far worse.
In addition, paracetamol was provided
to the subjects to be used as an analgesic
when required; the amount taken was used
as a measure of pain. Also determined at
each visit were weight, pulse, blood pres-
sure and temperature, and blood variables
of white blood cell count, hemoglobin,
polymorphs, platelet count, erythrocyte
sedimentation rate (ESR), alkaline phos-
phatase (AP), aspartate aminotransferase
(AST), alanine aminotransferase (ALT),
gamma-glutamyltransferase (,yGT), biliru-
bin, albumin, sodium, potassium, bicar-
bonate, urea, and creatinine. The patients
were examined also for other abnormalities,
including FBA film abnormalities, mental
impairment, and inflammation or desqua-
mation ofthe skin.
Results
The results were analyzed by SPSSX pack-
age (8). Two-way contingency tables were
assessed by Fisher's exact test and the good-
ness ofX% test. Differences in ratings were
assessed by Kendall's rank correlation coef-
ficient. Table 1 shows the nature of the
arthritis presented by the patients in the
first visit. The affected joints were 7 necks,
7 backs, 5 shoulders, 1 elbow, 12 wrists, 2
hands, 3 knuckles, 4 hips, 25 knees, 1
ankle, 3 feet, and 10 toes. There were no
significant locational differences, nor a dif-
ference in average severity of arthritis
between the two groups. Pain on passive
movement was present at the first visit in
56 (60%) of the affected joints, as was
swelling, warmth, or deformity. Restricted
movement was present in 62 (67%) of the
affected joints.
Two patients, one each in the placebo
and boron groups, dropped out ofthe trial
before the second examination-the place-
bo patient probably ceased participation
because of the lack of response to treat-
ment, and the boron patient because of
intercurrent medical problems. Neither
had improved nor worsened during the
short participation in the trial. Table 2
illustrates the responses of the remaining
18 patients after three weeks of study.
Although slightly more patients on boron
(four) than on the placebo (two) claimed to
have improved during the first 3 weeks, 12
claimed either to have worsened or stayed
the same. Statistically, the groups showed
Table 1. Characteristics of study subjects.
Variable Boron group Placebo group All subjects
Age 64.9 64.0 64.5
Years of arthritis 6.3 6.4 6.4
Number ofjoints affected 4.2 5.1 4.7
Severity ofjoints affected 1.7 1.9 1.8
With pain on movement (%) 50.0 69.0 60.0
With swelling, etc. (%) 50.0 69.0 60.0
With restricted movement(%) 64.0 69.0 67.0
Palliatives per day priorto visit 1 0.9 1.8 1.3
Table 2. Characteristics of patients after 3 weeks on trial.
Variable Boron group Placebo group All subjects
Number ofjoints affected 4.2 5.7 4.9
Condition ofworstjoint 4.1 4.6 4.3
Condition of all joints 3.7 3.5 3.6
With pain on movement 1%) 45.0 65.0 56.0
With swelling, etc. (%) 55.0 61.0 58.0
With restricted movement M%) 61.0 65.0 63.0
Palliatives per day between weeks 0 and 3 2.3 2.7 2.5
Table 3. Characteristics of patients after 8 weeks on trial.
Variable Boron group Placebo group All subjects
Number ofjoints affected 4.0 5.8 4.9
Condition ofworstjoint 3.3 4.6 4.1
Condition of all joints 3.0 3.9 3.6
With pain on movement (%) 27.0 70.0 54.0
With swelling, etc. (%) 46.0 57.0 53.0
With restricted movement (%) 54.0 70.0 64.0
Palliatives per day between visits 1 and 3 0.8 2.5 1.8
Table 4. Ancillary clinical, hematological and biochemical data.
Values of patients Values of patients Overall
Variable on supplement for 8 weeks atfirstvisit or on placebo mean
Weight 62.8 a 71.3 68.9
Pulse 73.9 73.9 73.9
Blood pressure 138/81 147/80 144/80
Temperature 36.9 36.9 36.9
White cell count 7.3 7.5 7.5
Hemoglobin 13.1 13.7 13.5
Polymorphs 4.2 4.6 4.5
Lymphocytes 2.2 2.0 2.0
Platelets 328.1 301.2 309.0
ESR 19.3 21.9 21.2
AP 78.7 84.3 82.6
AST 23.7 22.9 23.1
ALT 20.9 29.9 27.2
yGT 20.7 26.3 24.7
Bilirubin 7.0 6.7 6.8
Albumin 42.8 42.0 42.2
Sodium 139.9 140.5 140.3
Potassium 4.4 4.2 4.3
Bicarbonate 26.7 27.0 26.9
Chloride 102.7 104.0 103.6
Urea 6.7 6.9 6.8
Creatinine 0.09 0.09 0.09
Abbreviations: ESR, erythrocyte sedimentation rate; AP, alkaline phosphatase; AST, aspartame aminotransferase;
ALT, alanine aminotransferase; yGT, gamma glutamyltransferase. a Difference largely caused by weight loss in
one woman who was laterfound to have Hodgkin's lymphoma.
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no significant difference in their responses
at this time.
Between week 3 and the last examina-
tion at week 8, three additional patients
dropped out ofthe trial, apparently because
of a significant deterioration in condition;
two were on the boron supplement, the
other on the placebo. Table 3 shows the
responses of the remaining 15 patients
after 8 weeks on the trial; seven patients
taking the boron supplement and one tak-
ing the placebo claimed improvement,
while the remaining two patients taking
the boron supplement and seven patients
taking the placebo claimed to have wors-
ened or stayed the same. The favorable
response to the boron supplement was sig-
nificant (P<0.05, Fisher's exact test) and
was confirmed by the doctor conducting
the trial.
As shown in Table 3, on the last visit,
the average condition ofall patients' joints
was 3.3 for those taking the boron supple-
ment, and 3.9 for those taking the place-
bo; the difference was significant (p<0.05,
Kendall's rank correlation coefficient of
0.34). There was also significantly less pain
on passive movement in patients taking
the boron supplement (p<0.001).
Other observations during the trial were
that results did not vary by gender, and
those who had suffered arthritis for a
longer period of time did not respond as
well as those with more recent arthritis.
Also, older persons tended to show a
poorer response than younger ones.
People under 60 years of age generally
responded within a month, while those
between 60 and 70 needed up to two
months to respond.
Table 4 shows that there were no appar-
ent side effects to the boron supplementa-
tion. The boron supplementation had no
significant effect on the clinical, hematolog-
ical, and biochemical variables examined.
In summary, of those starting the trial,
50% receiving the boron supplement
improved compared to only 10% receiving
the placebo. Considering only those who
completed the trial, 71% improved while
taking the boron supplement. The find-
ings suggest that boron (as sodium tetrabo-
rate decahydrate) is safe and beneficial in
the treatment ofosteoarthritis.
Conclusion
In conclusion, over 30 years ofaccumulat-
ing evidence indicates that boron is essen-
tial for healthy bones and joints. Both
epidemiologic and controlled animal and
human experiments suggest that boron
supplementation in amounts found in
some diets throughout the world is effec-
tive in preventing or treating various forms
of arthritis. Thus, boron is a nutrient and
therefore should not be considered a poi-
son or a pharmaceutical. Because boron is
ofapparent clinical and nutritional impor-
tance, efforts should be expanded to assure
that people consume enough of this
important element every day.
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